001     165513
005     20240403113221.0
024 7 _ |a 10.1007/s12311-022-01484-3
|2 doi
024 7 _ |a pmid:36208403
|2 pmid
024 7 _ |a 1473-4222
|2 ISSN
024 7 _ |a 1473-4230
|2 ISSN
024 7 _ |a altmetric:136936544
|2 altmetric
037 _ _ |a DZNE-2022-01661
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bourcier, Dax
|b 0
245 _ _ |a French Translation and Cross-cultural Adaptation of the Scale for the Assessment and Rating of Ataxia.
260 _ _ |a London
|c 2023
|b Dunitz
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1700493504_2202
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The Scale for the Assessment and Rating of Ataxia (SARA) is a widely used scale for assessing the severity of ataxia in clinics, natural history studies, and treatment trials worldwide. However, no French translation with validated cross-cultural adaptation is available. This study aimed to translate and adapt the SARA into French. The translation process was conducted according to the ISPOR guidelines for the translation and cultural adaptation process for patient-reported outcomes. A total of five translators, an expert committee, and two physiotherapists took part in the process to assess and ensure comprehension and language equivalences of the final French version. A few misinterpretations were pointed out during the translation process and were changed accordingly by the translation team. The French version of the SARA is ready to be used in clinical and research settings with French-speaking populations living with ataxia.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Ataxia
|2 Other
650 _ 7 |a Cross-cultural adaptation
|2 Other
650 _ 7 |a ISPOR guidelines
|2 Other
650 _ 7 |a Psychometric properties
|2 Other
650 _ 7 |a Translation
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cross-Cultural Comparison
|2 MeSH
650 _ 2 |a Surveys and Questionnaires
|2 MeSH
650 _ 2 |a Reproducibility of Results
|2 MeSH
650 _ 2 |a Psychometrics
|2 MeSH
650 _ 2 |a Language
|2 MeSH
650 _ 2 |a Cerebellar Ataxia
|2 MeSH
700 1 _ |a Bélair, Nicolas
|b 1
700 1 _ |a Pedneault-Tremblay, Élyse-Anne
|b 2
700 1 _ |a Lessard, Isabelle
|b 3
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 4
|u dzne
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 5
|u dzne
700 1 _ |a Rahn, Caroline
|b 6
700 1 _ |a Brais, Bernard
|b 7
700 1 _ |a Duchesne, Elise
|b 8
700 1 _ |a Gagnon, Cynthia
|0 0000-0003-2829-8470
|b 9
|e Corresponding author
773 _ _ |a 10.1007/s12311-022-01484-3
|0 PERI:(DE-600)2071266-2
|n 6
|p 1118 - 1122
|t The Cerebellum
|v 22
|y 2023
|x 1473-4222
856 4 _ |u https://link.springer.com/article/10.1007/s12311-022-01484-3
856 4 _ |u https://pub.dzne.de/record/165513/files/DZNE-2022-01661_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/165513/files/DZNE-2022-01661_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:165513
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810314
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811275
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2023
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-02-02
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CEREBELLUM : 2022
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-24
920 1 _ |0 I:(DE-2719)1011001
|k AG Klockgether
|l Patient Studies
|x 0
920 1 _ |0 I:(DE-2719)5000063
|k AG Synofzik
|l Systems Neurodegeneration
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)5000063
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21